Daunorubicin

"Daunorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.

Descriptor ID	D003630
MeSH Number(s)	D02.455.426.559.847.562.050.200 D04.615.562.050.200 D09.408.051.059.200
Concept/Terms	Daunorubicin Daunorubicin Daunomycin Rubomycin Dauno-Rubidomycine Dauno Rubidomycine Rubidomycin Daunoblastin Daunoblastin Daunoblastine NSC-82151 NSC-82151 NSC 82151 NSC82151 Cerubidine Cerubidine Daunorubicin Hydrochloride Daunorubicin Hydrochloride Hydrochloride, Daunorubicin

Below are MeSH descriptors whose meaning is more general than "Daunorubicin".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Polycyclic Aromatic Hydrocarbons [D02.455.426.559.847]
Naphthacenes [D02.455.426.559.847.562]
Anthracyclines [D02.455.426.559.847.562.050]
Daunorubicin [D02.455.426.559.847.562.050.200]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Naphthacenes [D04.615.562]
Anthracyclines [D04.615.562.050]
Daunorubicin [D04.615.562.050.200]
Carbohydrates [D09]
Glycosides [D09.408]
Aminoglycosides [D09.408.051]
Anthracyclines [D09.408.051.059]
Daunorubicin [D09.408.051.059.200]

Below are MeSH descriptors whose meaning is related to "Daunorubicin".

Below are MeSH descriptors whose meaning is more specific than "Daunorubicin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Daunorubicin" by people in this website by year, and whether "Daunorubicin" was a major or minor topic of these publications.

Bar chart showing 10 publications over 10 distinct years, with a maximum of 1 publications in 2005 and 2006 and 2011 and 2012 and 2013 and 2015 and 2018 and 2019 and 2021 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	0	1
2006	0	1	1
2011	0	1	1
2012	0	1	1
2013	1	0	1
2015	0	1	1
2018	0	1	1
2019	0	1	1
2021	0	1	1
2022	0	1	1

Below are the most recent publications written about "Daunorubicin" by people in Profiles.

Elsayed AH, Cao X, Mitra AK, Wu H, Raimondi S, Cogle C, Al-Mansour Z, Ribeiro RC, Gamis A, Kolb EA, Aplenc R, Alonzo TA, Meshinchi S, Rubnitz J, Pounds S, Lamba JK. Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. J Clin Oncol. 2022 03 01; 40(7):772-783.

View in: PubMed
Schmucker AM, Leiby BE, Wilde L. Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2022 03; 22(3):e206-e212.

View in: PubMed
Kasner MT. Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia. Clin Adv Hematol Oncol. 2019 Nov; 17(11):604-606.

View in: PubMed
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res. 2018 09; 72:92-95.

View in: PubMed
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep; 100(9):1172-9.

View in: PubMed
Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1040-5.

View in: PubMed
Roboz GJ, Wissa U, Ritchie EK, Gergis U, Mayer S, Scandura JM, Christos PJ, Feldman EJ. Are low-intensity induction strategies better for older patients with acute myeloid leukemia? Leuk Res. 2012 Apr; 36(4):407-12.

View in: PubMed
Scandura JM, Roboz GJ, Moh M, Morawa E, Brenet F, Bose JR, Villegas L, Gergis US, Mayer SA, Ippoliti CM, Curcio TJ, Ritchie EK, Feldman EJ. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011 Aug 11; 118(6):1472-80.

View in: PubMed
Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006 Jul; 5(7):1854-63.

View in: PubMed
Pasello M, Hattinger CM, Stoico G, Manara MC, Benini S, Geroni C, Mercuri M, Scotlandi K, Picci P, Serra M. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. Eur J Cancer. 2005 Sep; 41(14):2184-95.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement